AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase III clinical study titled A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES). The study aims to assess the efficacy and safety of benralizumab in treating patients with HES, a rare and potentially life-threatening condition characterized by high levels of eosinophils.
The intervention being tested is benralizumab, a biological treatment administered via subcutaneous injection every four weeks. It is designed to reduce eosinophil levels and manage symptoms in patients with HES.
The study follows a randomized, parallel-group design with quadruple masking (participant, care provider, investigator, and outcomes assessor) to ensure unbiased results. The primary purpose is treatment, comparing benralizumab against a placebo.
The study began on July 20, 2020, and is currently active but not recruiting. The primary completion date is not specified, but the last update was submitted on August 5, 2025, indicating ongoing progress.
This study could significantly impact AstraZeneca’s stock performance and investor sentiment, especially if benralizumab proves effective. Success in this trial may position AstraZeneca favorably against competitors in the biologics market for rare diseases.
The study is ongoing, with further details available on the ClinicalTrials portal.